// COMPANY
Vevo Therapeutics
SECTOR NULLMENTIONS 2LAST SEEN JUNE 8, 2026
// OVERVIEW
Vevo Therapeutics is developing novel medicines for cancer by harnessing AI, cell-line and patient-derived xenograft models and single cell techniques.
// RECENT MENTIONS
// SIGNALS
2 SIGNALS
01
m_and_a·Axios Pro Rata·JUNE 8, 2026
“Incyte agreed to acquire Vega Therapeutics… for up to $2b ($1.25b upfront) from VC-backed Star Therapeutics.”
02
funding·T1 Scout·MAY 31, 2026
Source→AI-extracted from podcast / newsletter / paper summaries. May contain errors.